|
2023 Conference Publication Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapseSwain, F., Burgess, M., Kempe, S., Sabdia, M., Wight, J., Hawkes, E., Mutsando, H., Talaulikar, D., Merida de Long, L., Hawula, Z., Birch, S., Wyche, P., Gandhi, M. K. and Keane, C. (2023). Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_191 |
|
2023 Conference Publication Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCLVerner, E., Johnston, A., Pati, N., Hawkes, E., Lee, H. P., Cochrane, T., Cheah, C. Y., Filshie, R., Purtill, D., Sia, H., Enjeti, A. K., Brown, C., Murphy, N., Curnow, J., Lee, K., Gandhi, M. K., Butcher, B. E. and Trotman, J. (2023). Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_313 |
|
2023 Conference Publication Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphomaTobin, J. W., Tsang, H., Patch, A., Keane, C., Law, S. C., Gunawardana, J., Blombery, P., Thompson, E. R., Sabdia, M. B., De Long, L. M., Nath, K., Kazakoff, S. H., Cheah, C., Amanuel, B., Cochrane, T., Butler, J., Johnston, A., Shanavas, M., Li, L., Shelton, V., Hershenfeld, S., Kridel, R., Seymour, J. F., MacManus, M. and Gandhi, M. K. (2023). Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_189 |
|
2023 Journal Article Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemiaBurgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631 |
|
2023 Journal Article A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphomaGeorge, Hannah, Gunawardana, Jay, Keane, Colm, Hicks, Rod J. and Gandhi, Maher K. (2023). A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma. Internal Medicine Journal, 53 (7), 1105-1109. doi: 10.1111/imj.16078 |
|
2023 Journal Article Genetic susceptibility to EBV-related diseaseGandhi, Maher K. (2023). Genetic susceptibility to EBV-related disease. Blood, 141 (13), 1499-1500. doi: 10.1182/blood.2022019180 |
|
2023 Journal Article EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohortAgrawal, Prashasti, David, Kevin A., Chen, Zhengming, Sundaram, Suchitra, Kim, Seo-Hyun, Vaca, Ryan, Lin, Yong, Singer, Samuel, Malecek, Mary-Kate, Carter, Jordan, Zayac, Adam, Kim, Myung Sun, Reddy, Nishitha, Ney, Douglas, Habib, Alma, Strouse, Christopher, Graber, Jerome, Bachanova, Veronika, Salman, Sidra, Vendiola, Jean A., Hossain, Nasheed, Tsang, Mazie, Major, Ajay, Gandhi, Maher K., Keane, Colm, Bond, David A., Folstad, Matthew, Chang, Julie, Mier-Hicks, Angel ... Martin, Peter (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia and Lymphoma, 64 (5), 1026-1034. doi: 10.1080/10428194.2023.2191152 |
|
2023 Journal Article Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 StudyTrotman, Judith, Presgrave, Peter, Carradice, Duncan P., Lenton, Douglas Stuart, Gandhi, Maher K., Cochrane, Tara, Badoux, Xavier, Carlson, Julia, Nkhoma, Gloria, Butcher, Belinda, Nikpour, Armin, Fulham, Michael and Johnston, Anna M. (2023). Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. HemaSphere, 7 (3), e836. doi: 10.1097/HS9.0000000000000836 |
|
2023 Journal Article Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphomaCasey, Mika, Segawa, Kane, Law, Soi Cheng, Sabdia, Muhamamed Bilal, Nowlan, Bianca, Salik, Basit, Lee, Carol, Winterford, Clay, Pearson, Sally, Madore, Jason, Dougall, William C., Gandhi, Maher K. and Nakamura, Kyohei (2023). Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. Leukemia, 37 (2), 379-387. doi: 10.1038/s41375-022-01794-9 |
|
2023 Conference Publication ANALYSIS OF THE GENETIC LANDSCAPE IN ELDERLY DIFFUSE LARGE B CELL LYMPHOMA AGED ≥ 75 YEARS IDENTIFIES NEW TARGETABLE MUTATIONSRijal, Sewa, Lim, Jun Hee, Smyth, Lillian, Coombes, Caitlin, Jain, Sanjiv, Saxena, Kartik, Trotman, Judith, Verner, Emma, Gandhi, Maher K., Gandhi, Kaushal and Talaulikar, Dipti (2023). ANALYSIS OF THE GENETIC LANDSCAPE IN ELDERLY DIFFUSE LARGE B CELL LYMPHOMA AGED ≥ 75 YEARS IDENTIFIES NEW TARGETABLE MUTATIONS. HOBOKEN: WILEY. |
|
2022 Conference Publication Identification of Genetic Subtypes in Follicular LymphomaShelton, Victoria, Isaev, Keren, Liu, Ting, Silva, Anjali, Detroja, Rajesh, Bakhtiari, Mehran, Calvente, Lourdes, Hong, Michael, Modi, Saloni, Hershenfeld, Samantha A., Ludvigsen, Maja, d'Amore, Francesco Annibale, Brodtkorb, Marianne, Johnson, Nathalie A., Baetz, Tara, LeBrun, David, Tobin, Josh, Gandhi, Maher K., Mungall, Andrew J., Steidl, Christian, Delabie, Jan, Tremblay-Lemay, Rosemarie, Kahl, Brad S., Evens, Andrew M and Kridel, Robert (2022). Identification of Genetic Subtypes in Follicular Lymphoma. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-164610 |
|
2022 Journal Article Crebbp mutations are associated with shorter time to progression in limited-stage follicular lymphoma treated with radiationHershenfeld, Samantha A., Shelton, Victoria, Bakhtiari, Mehran, Calvente, Lourdes, Lajkosz, Katherine, Isaev, Keren, Silva, Anjali, Liu, Ting, Brodtkorb, Marianne, d'Amore, Francesco Annibale, Ludvigsen, Maja, Madsen, Charlotte, Hamilton-Dutoit, Stephen, Gandhi, Maher, Tobin, Joshua W.D., Baetz, Tara, LeBrun, David, Johnson, Nathalie A., Mungall, Andrew J., Crump, Michael, Delabie, Jan, Gospodarowicz, Mary, Hodgson, David, Hong, Michael, Kukreti, Vishal, Kuruvilla, John, Prica, Anca, Tremblay-Lemay, Rosemarie, Tsang, Richard and Kridel, Robert (2022). Crebbp mutations are associated with shorter time to progression in limited-stage follicular lymphoma treated with radiation. Blood, 140 (S1), 3532-3533. doi: 10.1182/blood-2022-156571 |
|
2022 Journal Article The PO4-tential for less toxic CAR T-cell therapiesTobin, Joshua W.D., Green, Michael R. and Gandhi, Maher K. (2022). The PO4-tential for less toxic CAR T-cell therapies. Cancer Immunology Research, 10 (12), 1422-1422. doi: 10.1158/2326-6066.cir-22-0793 |
|
2022 Journal Article Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases RegistryLymphoma and Related Diseases Registry Investigators, Gandhi, Maher K. and Keane, Colm (2022). Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Medical Research Methodology, 22 (1) 266, 1-10. doi: 10.1186/s12874-022-01728-0 |
|
2022 Conference Publication Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin LymphomaGunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17 |
|
2022 Journal Article CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin LymphomaGandhi, Maher K and Keane, Colm (2022). CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma. Haematologica, 108 (4), 1-3. doi: 10.3324/haematol.2022.281440 |
|
2022 Journal Article Neoantigens: the next frontier in precision immunotherapy for B-cell lymphoproliferative disordersSabdia, Muhammed B., Patch, Ann-Marie, Tsang, Hennes and Gandhi, Maher K. (2022). Neoantigens: the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders. Blood Reviews, 56 100969, 100969. doi: 10.1016/j.blre.2022.100969 |
|
2022 Journal Article Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMa, Man Chun John, Tadros, Saber, Bouska, Alyssa, Heavican, Tayla, Yang, Haopeng, Deng, Qing, Moore, Dalia, Akhter, Ariz, Hartert, Keenan, Jain, Neeraj, Showell, Jordan, Ghosh, Sreejoyee, Street, Lesley, Davidson, Marta, Carey, Christopher, Tobin, Joshua, Perumal, Deepak, Vose, Julie M., Lunning, Matthew A., Sohani, Aliyah R., Chen, Benjamin J., Buckley, Shannon, Nastoupil, Loretta J., Davis, R. Eric, Westin, Jason R., Fowler, Nathan H., Parekh, Samir, Gandhi, Maher, Neelapu, Sattva ... Green, Michael R. (2022). Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica, 107 (3), 690-701. doi: 10.3324/haematol.2020.274258 |
|
2021 Journal Article Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomasBednarska, Karolina, Nath, Karthik, Nicol, William and Gandhi, Maher K. (2021). Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas. Blood Reviews, 50 100832, 100832. doi: 10.1016/j.blre.2021.100832 |
|
2021 Journal Article Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapyShanavas, Mohamed, Law, Soi‐Cheng, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Li, Zhixiu, Merida de Long, Lilia, Nath, Karthik, Sabdia, Muhammed B., Gunawardana, Jay, Gandhi, Maher K. and Keane, Colm (2021). Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 10 (11) e1351, e1351. doi: 10.1002/cti2.1351 |
